Alembic Ltd

₹ 92.9 -0.48%

03 Jul - close price

alembiclimited.com BSE: 506235 NSE: ALEMBICLTD

About

Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.^[1]

Key Points

Business Segments
A) Real Estate (~80% in FY24 vs 59% in FY22): ^[1] ^[2] The company is involved in the construction of residential & commercial real estate projects. It also leases commercial properties. ^[3] Real Estate business experienced strong growth between FY23-FY24 bolstered by strong demand and higher property prices. ^[4]

Website BSE NSE

Market Cap ₹ 2,384 Cr.
Current Price ₹ 92.9
High / Low ₹ 122 / 70.5
Stock P/E 19.2
Book Value ₹ 32.0
Dividend Yield 2.58 %
ROCE 17.5 %
ROE 14.9 %
Face Value ₹ 2.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 53.1%

Cons

Earnings include an other income of Rs.72.8 Cr.
Working capital days have increased from 90.4 days to 138 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Consumer Discretionary Realty Realty Residential, Commercial Projects

Part of BSE Consumer Discretionary BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	36.10	35.65	31.15	37.94	47.51	49.08	51.10	55.97	58.22	47.89	54.04	72.28	57.73
	23.32	25.54	21.53	24.79	24.14	29.63	32.72	30.26	32.21	29.31	31.52	45.23	38.18
Operating Profit	12.78	10.11	9.62	13.15	23.37	19.45	18.38	25.71	26.01	18.58	22.52	27.05	19.55
OPM %	35.40%	28.36%	30.88%	34.66%	49.19%	39.63%	35.97%	45.94%	44.68%	38.80%	41.67%	37.42%	33.86%
	-8.64	2.59	47.86	2.21	1.95	1.89	65.59	4.25	2.78	3.46	64.80	2.10	2.41
Interest	0.04	0.05	0.05	0.26	0.33	0.34	0.51	0.52	0.45	0.42	0.40	0.37	0.37
Depreciation	1.61	1.74	1.77	2.57	1.38	2.41	2.59	2.59	2.66	2.70	2.72	3.34	3.25
Profit before tax	2.49	10.91	55.66	12.53	23.61	18.59	80.87	26.85	25.68	18.92	84.20	25.44	18.34
Tax %	-72.29%	13.11%	7.60%	9.90%	12.41%	9.41%	5.28%	4.32%	11.10%	9.51%	10.18%	12.50%	48.04%
	4.29	9.48	51.43	11.29	20.68	16.84	76.60	25.69	22.83	17.12	75.63	22.26	9.53
EPS in Rs	0.17	0.37	2.00	0.44	0.81	0.66	2.98	1.00	0.89	0.67	2.95	0.87	0.37
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	144	134	147	125	124	74	72	76	123	152	214	232
	134	128	140	114	106	70	62	63	85	96	125	144
Operating Profit	10	6	7	11	18	4	11	13	38	56	90	88
OPM %	7%	5%	5%	9%	15%	5%	15%	17%	31%	37%	42%	38%
	21	25	25	37	29	93	10	89	54	55	75	73
Interest	1	0	0	0	0	0	0	0	0	1	2	2
Depreciation	6	6	5	4	3	3	4	4	6	7	10	12
Profit before tax	23	25	27	44	45	94	17	97	85	103	152	147
Tax %	-3%	2%	-3%	5%	8%	0%	19%	12%	7%	10%	7%	15%
	24	25	27	42	41	94	13	86	79	93	142	125
EPS in Rs	0.90	0.93	1.03	1.56	1.60	3.64	0.52	3.34	3.09	3.62	5.53	4.85
Dividend Payout %	17%	16%	19%	13%	12%	16%	38%	54%	71%	66%	43%	49%

Compounded Sales Growth
10 Years:	6%
5 Years:	26%
3 Years:	23%
TTM:	8%

Compounded Profit Growth
10 Years:	17%
5 Years:	67%
3 Years:	13%
TTM:	-12%

Stock Price CAGR
10 Years:	11%
5 Years:	-6%
3 Years:	8%
1 Year:	-22%

Return on Equity
10 Years:	11%
5 Years:	12%
3 Years:	14%
Last Year:	15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	53	53	53	53	51	51	51	51	51	51	51	51
Reserves	211	295	314	395	361	432	775	962	778	757	802	770
	0	9	0	0	0	0	0	0	0	9	14	11
	91	64	81	73	57	51	109	130	119	128	142	126
Total Liabilities	356	421	449	522	470	534	936	1,144	948	946	1,010	958
	169	146	171	179	209	225	261	294	318	366	406	470
CWIP	2	0	0	0	0	3	6	0	0	1	0	2
Investments	35	150	189	276	205	197	581	726	503	411	414	349
	149	124	89	67	55	109	88	124	127	168	190	138
Total Assets	356	421	449	522	470	534	936	1,144	948	946	1,010	958

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	22	10	52	24	22	5	-1	-22	35	25	81	117
	5	-5	-47	-23	68	57	-35	23	11	23	-22	-52
	-25	-5	-5	-3	-89	-6	-15	-6	-46	-48	-58	-67
Net Cash Flow	2	-0	-0	-2	1	56	-52	-5	-0	0	2	-1
Free Cash Flow	22	11	38	14	-1	-16	-44	-55	10	-31	30	41
CFO/OP	222%	172%	771%	246%	145%	187%	8%	-102%	108%	42%	107%	156%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	122	76	54	74	40	44	66	72	67	42	47	48
Inventory Days	880	659	438	247	289	411	2,112	2,885	5,118	3,694		249
Days Payable	200	144	128	125	202	151	675	635	993	1,213		110
Cash Conversion Cycle	801	591	364	195	126	304	1,504	2,322	4,191	2,523	47	187
Working Capital Days	235	172	39	20	13	28	96	231	127	75	58	138
ROCE %	9%	8%	8%	10%	10%	21%	2%	10%	10%	12%	18%	17%

Insights

In beta

Mar 2016

Mar 2017

Mar 2020

Mar 2021

Sep 2022

Mar 2025

Stake in Alembic Pharmaceuticals Limited
%

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx	x	x	x		x
xxx	xxx	xxx	xxx		xxx
x	x	x	x		x
xxx	xxx				xxx
					xxx
x.xx	x.xx

Please log in to see hidden values.

Co-generation power installed capacity
MW

Land bank
acres

Wind power installed capacity
MW

Permanent workforce
count

Real estate project bookings
%

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%
	0.72%	0.85%	0.89%	1.07%	1.42%	1.97%	1.78%	1.65%	1.50%	1.38%	1.29%	1.25%
	3.93%	3.40%	0.04%	0.04%	0.04%	0.08%	0.06%	0.05%	0.05%	0.05%	0.05%	0.05%
	24.46%	24.87%	28.17%	28.02%	27.66%	27.07%	27.27%	27.41%	27.57%	27.68%	27.78%	27.81%
No. of Shareholders	81,732	82,947	94,012	99,130	98,478	1,02,249	1,07,423	1,06,732	1,07,510	1,06,470	1,04,103	1,02,008

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	65.77%	63.71%	64.57%	67.62%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%
	5.60%	1.16%	1.04%	1.80%	1.60%	1.12%	0.70%	1.07%	1.65%	1.25%
	0.09%	5.35%	5.81%	5.94%	4.34%	4.69%	3.94%	0.04%	0.05%	0.05%
	0.00%	0.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	28.54%	29.11%	28.58%	24.64%	23.18%	23.31%	24.48%	28.02%	27.41%	27.81%
No. of Shareholders	56,623	66,838	61,605	53,132	67,238	80,135	82,339	99,130	1,06,732	1,02,008

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Alembic Ltd

Alembic Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings